SynthesisLung2017
Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review.
Synthesis in Lung, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 23 citations in OpenAlex.
- Healthcare Expenditures and Reimbursement Patterns in Idiopathic Pulmonary Fibrosis: A 10-Year Single-Center Retrospective Cohort Study in Turkey.Healthcare (Basel, Switzerland) · 2025Article
- Validation of a Novel Clinical Dyspnea Scale - A Retrospective Pilot Study.The American journal of hospice & palliative care · 2024Article
- The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- Cost drivers in the pharmacological treatment of interstitial lung disease.Respiratory research · 2021Observational
- Increased respiratory morbidity in individuals with interstitial lung abnormalities.BMC pulmonary medicine · 2020Article
- Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis.European clinical respiratory journal · 2020Article
- Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension.American journal of respiratory cell and molecular biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is an incurable, debilitating disease which impairs lung function and eventually leads to death. Currently, there is a lack of effective modifying therapies and treatments for IPF as the underlying epidemiological mechanism is not clearly understood. This leads to difficulty in diagnosing and managing IPF, which results in a high incurment of disease-associated cost. Even though IPF poses a substantial economic burden, there is a lack of research available on cost triggers and healthcare utilization, which can be a barrier to future economic evaluations of new medicines for IPF.
objectivesWe aimed to conduct a systematic literature review (SLR) to identify the key cost-generating events of IPF and to gather any related costing information.
resultsThe data showed that the main events triggering high resource use in patients were the symptoms of IPF progression along with comorbidities and lung transplantations. These events result in a high economic impact through the use of medications, health care professionals, and hospital stays.
conclusionMore research is needed to identify the direct, and indirect, relationships between IPF events and the costs they generate. This would help to further evaluate the area of need for future health technologies and to understand what events should be targeted to reduce the global economic burden of IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.